NEWSLETTERS - The Huntington's Disease News
By AICH - Roma Onlus
View this email in your browser
Newsletters 23 Sett.  2016
Huntington's disease news
Sett. 19 2016
Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease

Pridopidine Demonstrates Slowing of Progression of Huntington Disease in PRIDE-HD Study as Measured by Total Functional Capacity

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announces top-line results from the exploratory Phase 2 PRIDE-HD study. This was a 52-week, dose-ranging trial of pridopidine twice daily versus placebo, in the treatment of Huntington disease (HD). The study was directed at measuring improvement in motor function and the effect on HD progression.

Sett 22, 2016
Teva Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD)

SD-809 demonstrates a statistically significant improvement in Abnormal Involuntary 
Movement Scale score in AIM-TD study

Adds to body of data supporting this promising breakthrough investigational therapy to 
address unmet patient need

Sett 16, 2016
Teva to Develop Unique Wearable Tech and Machine Learning Platform for Continuous Measurement & Analysis of Huntington Disease Symptoms in Collaboration with Intel

Platform aims to enhance understanding of disease progression and impact of treatment

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announces a collaboration with Intel Corporation to develop a unique wearable device and machine learning platform for use in Huntington disease (HD). This platform will continuously monitor and analyze key symptoms that impact daily living, in an effort to better understand disease progression and improve treatment evaluation.

Copyright © 2016 aichroma, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

Email Marketing Powered by Mailchimp